Product Usage: For Research Use Only – Not for Human or Veterinary Use
This product is not a drug, food, cosmetic, or dietary supplement and has not been evaluated by the FDA. It is strictly intended for in vitro research by qualified professionals. Any use in humans or animals is strictly prohibited and may violate federal, state, or local laws, including the Federal Food, Drug, and Cosmetic Act. No therapeutic or diagnostic application is implied or permitted. The purchaser assumes all responsibility for compliance with applicable regulations.
Tesamorelin / Ipamorelin Blend – 10/10mg
5mg/5mg lyophilized blend of Tesamorelin and Ipamorelin. Each component is separately studied in receptor-signaling research — Tesamorelin as a GHRH-receptor analog and Ipamorelin as a selective ghrelin-receptor secretagogue. Supplied at research-grade purity for laboratory use only.
$275.00
Researchers who buy this Tesamorelin / Ipamorelin research peptide blend are typically studying combined-receptor growth-hormone-axis signaling — pairing an extended-stability GHRH-receptor agonist with a selective ghrelin-receptor (GHS-R1a) agonist in a single fixed-ratio preparation. Each compound acts through a distinct receptor pathway; the summary below reflects the published preclinical and clinical literature on each component and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.
In this reference:
- What Is This Blend?
- Tesamorelin: Mechanism and Research
- Ipamorelin: Mechanism and Research
- Why Researchers Study This Combination
- Chemical Identity
- Purity, Storage & Quality
- Frequently Asked Questions
What Is This Blend?
This vial supplies a fixed-ratio, 10mg/10mg lyophilized combination of two distinct growth-hormone-axis research peptides: Tesamorelin, an FDA-approved-formulation-adjacent GHRH analog with extended pharmacokinetic stability, and Ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. Each compound is independently well-characterized in the published pharmacology literature, and their co-administration is a common research design for studying combined-receptor GH-axis stimulation rather than either receptor pathway in isolation.
Tesamorelin: Mechanism and Research
Tesamorelin is a synthetic GHRH-analog research peptide modified from the native GHRH(1-44) sequence to resist enzymatic degradation. It carries one of the most substantial human clinical-trial records of any compound in this catalog, because a pharmaceutical-grade formulation (Egrifta/Egrifta SV) is FDA-approved for a narrow indication — reduction of excess abdominal fat in HIV-associated lipodystrophy. A pivotal randomized controlled trial reported significant visceral-adipose-tissue reduction versus placebo (Falutz J, et al., N Engl J Med. 2007;357(23):2359-2370; PMID 18057338), and a 2026 meta-analysis of five RCTs confirmed this finding across the pooled trial base (PMID 41545261). A full literature review of Tesamorelin’s mechanism, chemical identity, and this clinical-trial record is available on its own dedicated page: Tesamorelin. That approval history applies to a distinct pharmaceutical formulation only — it does not extend to the research-grade material in this blend, which is sold strictly for laboratory research use.
Ipamorelin: Mechanism and Research
Ipamorelin is a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a), first characterized as the most receptor-selective compound in its class — activating GH-axis signaling in tested animal models with markedly less elevation of ACTH, cortisol, and prolactin than earlier, broader-acting secretagogue peptides (Raun K, et al., Eur J Endocrinol. 1998;139(5):552-561; PMID 9849822). A full literature review of Ipamorelin’s mechanism, chemical identity, and the one controlled human trial in which it has been studied (a gastrointestinal-motility indication, PMID 25331030) is available on its own dedicated page: Ipamorelin – 10mg.
Why Researchers Study This Combination
Because Tesamorelin and Ipamorelin engage two separate receptors in the same GH-axis signaling pathway — GHRHR and GHS-R1a, respectively — published pharmacology has proposed that co-administration may produce a more complete GH-axis stimulation profile than either compound alone, since the two mechanisms are not mutually redundant. Researchers studying combined-receptor GH-axis engagement, or comparing single-receptor versus dual-receptor stimulation protocols, are the typical audience for this fixed-ratio preparation. This combination-research design is distinct from, and should not be conflated with, the individual human clinical-trial evidence summarized on each compound’s own product page above — no published research has evaluated this specific fixed-ratio combination directly.
Chemical Identity
| Component 1 | Tesamorelin — 10mg |
| Component 2 | Ipamorelin — 10mg |
| Tesamorelin MW | ~5135.9 g/mol |
| Ipamorelin MW | ~711.9 g/mol |
| Appearance | White to off-white lyophilized powder |
Purity, Storage & Quality
First Class Science supplies this Tesamorelin / Ipamorelin blend at research-grade purity, with each component independently verified by third-party HPLC testing and mass spectrometry prior to blending. A Certificate of Analysis is available for every batch at our Certificate of Analysis page.
Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions.
Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.
Related Preparations
Laboratories designing protocols that isolate a single receptor pathway typically select the standalone Ipamorelin or Tesamorelin vial. A smaller Tesamorelin / Ipamorelin Blend – 5/5mg preparation of this same blend is also available, along with a related CJC-1295 / Ipamorelin Blend pairing Ipamorelin with a different, shorter-acting GHRH analog, and a triple-compound blend combining all three research peptides.
Frequently Asked Questions
What is the purity of this blend?
Each component is independently verified via third-party HPLC and mass-spectrometry testing prior to blending, with a Certificate of Analysis published for each lot.
How should this Tesamorelin / Ipamorelin blend be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.
Is this blend approved for human or animal use?
No. A distinct pharmaceutical-grade Tesamorelin formulation (Egrifta) is FDA-approved for a specific indication, but that approval does not extend to this research-grade blend. Ipamorelin is not an FDA-approved drug for any indication. Neither component of this specific blend has been evaluated by the FDA, and this product is sold exclusively for in vitro and laboratory research use.
Why are these two specific compounds combined?
Tesamorelin (a GHRH-receptor agonist) and Ipamorelin (a GHS-R1a agonist) engage two separate, non-redundant receptors in the GH-axis pathway. Researchers study the fixed-ratio combination to model dual-receptor stimulation, distinct from either compound’s single-receptor mechanism studied individually.
Has either compound been tested in humans?
Yes, independently. Tesamorelin (as its approved pharmaceutical formulation) was evaluated in a pivotal randomized controlled trial (PMID 18057338) and a 2026 meta-analysis (PMID 41545261). Ipamorelin was evaluated in a narrow phase 2 trial for postoperative gastrointestinal motility (PMID 25331030). Neither trial evaluated the fixed-ratio combination sold in this blend.
What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date for each component.
Shipping, Handling & Compliance
This blend ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.
Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or controlled clinical-trial contexts, examining each individual compound. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal. No published research has evaluated this specific fixed-ratio combination directly.
⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.